Dumont & Blake Investment Advisors’s REGENERX BIOPHARMACEUTICALS RGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-22,300
| Closed | -$10K | – | 207 |
|
|
2020
Q4 | $10K | Hold |
22,300
| – | – | ﹤0.01% | 194 |
|
|
2020
Q3 | $9K | Hold |
22,300
| – | – | ﹤0.01% | 183 |
|
|
2020
Q2 | $7K | Hold |
22,300
| – | – | ﹤0.01% | 173 |
|
|
2020
Q1 | $4K | Hold |
22,300
| – | – | ﹤0.01% | 167 |
|
|
2019
Q4 | $3K | Hold |
22,300
| – | – | ﹤0.01% | 180 |
|
|
2019
Q3 | $3K | Hold |
22,300
| – | – | ﹤0.01% | 178 |
|
|
2019
Q2 | $4K | Hold |
22,300
| – | – | ﹤0.01% | 177 |
|
|
2019
Q1 | $5K | Hold |
22,300
| – | – | ﹤0.01% | 178 |
|
|
2018
Q4 | $3K | Hold |
22,300
| – | – | ﹤0.01% | 175 |
|
|
2018
Q3 | $4K | Hold |
22,300
| – | – | ﹤0.01% | 179 |
|
|
2018
Q2 | $4K | Hold |
22,300
| – | – | ﹤0.01% | 181 |
|
|
2018
Q1 | $5K | Sell |
22,300
-38,312
| -63% | -$8.59K | ﹤0.01% | 185 |
|
|
2017
Q4 | $10K | Buy |
60,612
+20,000
| +49% | +$3.3K | ﹤0.01% | 194 |
|
|
2017
Q3 | $13K | Hold |
40,612
| – | – | 0.01% | 191 |
|
|
2017
Q2 | $11K | Sell |
40,612
-21,925
| -35% | -$5.94K | ﹤0.01% | 192 |
|
|
2017
Q1 | $18K | Hold |
62,537
| – | – | 0.01% | 178 |
|
|
2016
Q4 | $20K | Hold |
62,537
| – | – | 0.01% | 177 |
|
|
2016
Q3 | $23K | Hold |
62,537
| – | – | 0.01% | 169 |
|
|
2016
Q2 | $29K | Hold |
62,537
| – | – | 0.01% | 171 |
|
|
2016
Q1 | $44K | Hold |
62,537
| – | – | 0.02% | 159 |
|
|
2015
Q4 | $28K | Hold |
62,537
| – | – | 0.01% | 163 |
|
|
2015
Q3 | $26K | Hold |
62,537
| – | – | 0.01% | 155 |
|
|
2015
Q2 | $23K | Hold |
62,537
| – | – | 0.01% | 158 |
|
|
2015
Q1 | $16K | Hold |
62,537
| – | – | 0.01% | 157 |
|
|
2014
Q4 | $9K | Hold |
62,537
| – | – | ﹤0.01% | 156 |
|
|
2014
Q3 | $8K | Hold |
62,537
| – | – | ﹤0.01% | 152 |
|
|
2014
Q2 | $12K | Hold |
62,537
| – | – | 0.01% | 149 |
|
|
2014
Q1 | $12K | Hold |
62,537
| – | – | 0.01% | 145 |
|
|
2013
Q4 | $3K | Hold |
62,537
| – | – | ﹤0.01% | 145 |
|
|
2013
Q3 | $4K | Hold |
62,537
| – | – | ﹤0.01% | 145 |
|
|
2013
Q2 | $5K | Buy |
+62,537
| New | +$5K | ﹤0.01% | 121 |
|
Other funds holding RGN
Dumont & Blake Investment Advisors's RGN Position: Q1 2021 in Review
Dumont & Blake Investment Advisors sold out of REGENERX BIOPHARMACEUTICALS (RGN) in Q1 2021, closing a stake of 22,300 shares — an estimated $10K sold.
Dumont & Blake Investment Advisors first reported a position in RGN in Q2 2013 and held it in 31 quarters. The position peaked at $44K in Q1 2016. 1 fund tracked by Wall St. Rank holds RGN as of Q1 2021.
- Dumont & Blake Investment Advisors reported no remaining REGENERX BIOPHARMACEUTICALS position as of Q1 2021 after selling out during the quarter.
- Dumont & Blake Investment Advisors sold 22,300 REGENERX BIOPHARMACEUTICALS shares in Q1 2021, an estimated $10K.
- Dumont & Blake Investment Advisors first reported a position in REGENERX BIOPHARMACEUTICALS in Q2 2013 and held it in 31 quarters.
- Dumont & Blake Investment Advisors's REGENERX BIOPHARMACEUTICALS position peaked at $44K in Q1 2016.
- 1 fund tracked by Wall St. Rank held REGENERX BIOPHARMACEUTICALS as of Q1 2021.
Based on Dumont & Blake Investment Advisors's 13F filing for Q1 2021, filed 3 May 2021.